Author + information
- Kenechukwu Mezue,
- David Wheeler,
- Parasuram Krishnamoorthy,
- Peter Fumo,
- Srikanth Nagalla,
- Gregg Pressman and
- Janani Rangaswami
Background: Hemodialysis (HD) is independently associated with higher levels of platelet reactivity. However, previous studies measured platelet reactivity at only one single time point. The objective of this study is to investigate the variability of platelet reactivity within the HD cycle.
Methods: We measured platelet reactivity using light transmission aggregometry (VerifyNow), over two HD cycles (two pre-HD measurements, one inter-HD, and two post-HD) in 19 adult non-smoking patients with end-stage renal disease. Nine patients of the cohort were on aspirin during the study.
Results: For the non-aspirin group, there was a significant (-12.5%; p<0.05) decrease in aspirin reaction units (ARU) when comparing pre-HD and post-HD values (Figure 1). Inter-HD values were not significantly different from pre-HD or post-HD values. Pre-HD values for the same patient were highly variable with little predictive power for future pre-HD values (r=0.031). For the aspirin cohort, there was no significant difference between pre-HD, post HD and inter-HD ARU.
Conclusions: Patients on HD have significant variability in platelet activity during the HD cycle, with decreased platelet reactivity post-dialysis as compared to pre-dialysis. Aspirin intake reduces this variability. The inconsistency of intra-patient pre-HD platelet reactivity measurements suggests that, for both research and clinical practice, multiple measurements of platelet reactivity in HD patients may be necessary.
Poster Hall, Hall C
Friday, March 17, 2017, 10:00 a.m.-10:45 a.m.
Session Title: Considerations in Antiplatelet Therapy and in ACS
Abstract Category: 15. Interventional Cardiology: ACS/AMI/Hemodynamics and Pharmacology
Presentation Number: 1113-142
- 2017 American College of Cardiology Foundation